TR200102811T2 - Oral uygulama için, tolpersiyon içeren farmasötik preparat. - Google Patents

Oral uygulama için, tolpersiyon içeren farmasötik preparat.

Info

Publication number
TR200102811T2
TR200102811T2 TR2001/02811T TR200102811T TR200102811T2 TR 200102811 T2 TR200102811 T2 TR 200102811T2 TR 2001/02811 T TR2001/02811 T TR 2001/02811T TR 200102811 T TR200102811 T TR 200102811T TR 200102811 T2 TR200102811 T2 TR 200102811T2
Authority
TR
Turkey
Prior art keywords
tolpersion
oral administration
pharmaceutical preparation
preparation containing
mixture
Prior art date
Application number
TR2001/02811T
Other languages
English (en)
Inventor
Frantsits Werner
Original Assignee
Sanochemia Pharmazeutika Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanochemia Pharmazeutika Ag filed Critical Sanochemia Pharmazeutika Ag
Publication of TR200102811T2 publication Critical patent/TR200102811T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Farmasötik bir karisim, etki maddesi olarak rasemik bir karisim halindeki tolpersiyon ya da bunun bir tuzunu içermekte olup, bu 50/50-rasemat ya da tolpersiyonun (-)-izomerini daha yüksek oranda içeren bir rasemat olabilir. Oral uygulamaya yönelik bir farmasötik karisim kati ya da sivi, oral uygulanabilir farmasötik preparat seklinde fomüle edilmekte olup, 50/50-rasemat ya da (-)-izomerini veya (+)- izomerini daha yüksek oranda içeren rasemat halindeki tolpersiyon etki maddesi karisimdan insan vücuduna gecikmeli olarak, tercihen bagirsak sisteminde açiga çikmaktadir.
TR2001/02811T 1999-04-01 1999-11-16 Oral uygulama için, tolpersiyon içeren farmasötik preparat. TR200102811T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0059499A AT409083B (de) 1999-04-01 1999-04-01 Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung

Publications (1)

Publication Number Publication Date
TR200102811T2 true TR200102811T2 (tr) 2002-05-21

Family

ID=3494723

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02811T TR200102811T2 (tr) 1999-04-01 1999-11-16 Oral uygulama için, tolpersiyon içeren farmasötik preparat.

Country Status (23)

Country Link
US (1) US6500455B1 (tr)
EP (1) EP1165081B1 (tr)
JP (1) JP2002541107A (tr)
AT (1) AT409083B (tr)
AU (1) AU1136400A (tr)
CA (1) CA2366841C (tr)
CZ (1) CZ20013404A3 (tr)
DE (1) DE59912101D1 (tr)
EE (1) EE04833B1 (tr)
ES (1) ES2168241T3 (tr)
HR (1) HRPK20010706B1 (tr)
HU (1) HUP0200669A3 (tr)
IL (2) IL145559A0 (tr)
NO (1) NO20014738L (tr)
NZ (1) NZ514129A (tr)
PL (1) PL197545B1 (tr)
PT (1) PT1165081E (tr)
RU (1) RU2223098C2 (tr)
SK (1) SK13642001A3 (tr)
TR (1) TR200102811T2 (tr)
UA (1) UA71613C2 (tr)
WO (1) WO2000059508A1 (tr)
YU (1) YU67501A (tr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0300929A3 (en) * 2003-04-09 2005-06-28 Richter Gedeon Vegyeszet Analgetic and/or muscle relaxant pharmaceutical composition
DE10341923A1 (de) * 2003-09-11 2005-04-07 Heinl, Alexander, Dr.med. Verwendung von Tolperison
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE10359335A1 (de) * 2003-10-23 2005-05-25 Viatris Gmbh & Co. Kg Kombinationen aus Kaliumkanalöffnern und Natriumkanalinhibitoren oder Natriumkanal beeinflussenden Wirkstoffen zur Behandlung von Schmerzzuständen
AT500144A1 (de) * 2004-03-05 2005-11-15 Sanochemia Pharmazeutika Ag Tolperison enthaltende, pharmazeutische zubereitung mit steuerbarer wirkstofffreisetzung zur oralen verabreichung
MX2008013437A (es) * 2006-04-20 2009-03-06 Sanochemia Pharmazeutika Ag Metodo para administrar tolperisona.
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
MX2009002002A (es) * 2006-08-23 2009-07-22 Valeant Pharmaceuticals Int Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potasio.
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
KR20090083479A (ko) 2006-11-28 2009-08-03 밸리언트 파마슈티컬즈 인터내셔널 칼륨 채널 조절제로서의 1,4 디아미노 이환 레티가빈 유사체
AT505225A1 (de) * 2007-04-26 2008-11-15 Sanochemia Pharmazeutika Ag 0erfahren zur herstellung von hoch reinem 2,4'-dimethyl-3-piperidino-propiophenon (tolperison), dieses enthaltende pharmazeutische zusammensetzungen, sowie tolperison enthaltende wirkstoffformulierungen
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
HUP0700485A3 (en) * 2007-07-23 2010-01-28 Richter Gedeon Nyrt Pharmaceutical composition with controlled release containing tolperisone
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
US20100249423A1 (en) * 2009-03-09 2010-09-30 Sanochemia Pharmazeutika Ag Tolperisone controlled release tablet
CN102438597A (zh) 2009-03-09 2012-05-02 丁内沙·沙蒂尔阿尔·帕特尔 一种选自中枢性作用肌弛缓药类型的化合物的新型缓释制剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5154918A (en) * 1974-10-08 1976-05-14 Nippon Kayaku Kk Jozaino seizoho
JPS5191315A (ja) * 1975-02-06 1976-08-10 Anteinaensantoruperizonshirotsupunoseizoho
JPS5340779A (en) * 1976-09-21 1978-04-13 Nippon Kayaku Co Ltd Optically active tolpertisone, their preparation and pharmaceuticals containting the same
JPS58135806A (ja) * 1982-02-08 1983-08-12 Nippon Kayaku Co Ltd 多層コ−チング製剤
JPS6143108A (ja) * 1984-08-03 1986-03-01 Nippon Shinyaku Co Ltd 医薬品製剤及びその製造法
JPH0637389B2 (ja) * 1986-12-26 1994-05-18 北陸製薬株式会社 頻尿治療剤
JPH0720866B2 (ja) 1987-05-15 1995-03-08 三生製薬株式会社 エペリゾン又はトルペリゾン或いはそれらの塩類含有経皮適用製剤
IL87710A (en) * 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
MY115126A (en) * 1990-04-27 2003-04-30 Seikisui Chemical Co Ltd Percutaneously absorbable eperisone or tolperisone preparation.
US5128145A (en) * 1990-06-13 1992-07-07 Alza Corporation Dosage form for Parkinson's disease, spasticity and muscle spasms
TW209174B (tr) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
ATE154241T1 (de) * 1991-10-01 1997-06-15 Takeda Chemical Industries Ltd Mikropartikeln-zusammenfassung zur verlängerten freigabe und herstellung derselbe
US5811547A (en) * 1992-10-14 1998-09-22 Nippon Shinyaju Co., Ltd. Method for inducing crystalline state transition in medicinal substance

Also Published As

Publication number Publication date
CA2366841C (en) 2008-10-07
HRP20010706A2 (en) 2003-02-28
PT1165081E (pt) 2005-08-31
EP1165081B1 (de) 2005-05-25
EE04833B1 (et) 2007-06-15
HRPK20010706B1 (en) 2004-12-31
EE200100503A (et) 2003-02-17
NO20014738D0 (no) 2001-09-28
DE59912101D1 (de) 2005-06-30
PL197545B1 (pl) 2008-04-30
HUP0200669A3 (en) 2002-11-28
WO2000059508A1 (de) 2000-10-12
CZ20013404A3 (cs) 2002-02-13
IL145559A (en) 2008-12-29
ES2168241T1 (es) 2002-06-16
NO20014738L (no) 2001-10-23
NZ514129A (en) 2003-04-29
JP2002541107A (ja) 2002-12-03
YU67501A (sh) 2004-07-15
EP1165081A1 (de) 2002-01-02
ATA59499A (de) 2001-10-15
UA71613C2 (uk) 2004-12-15
RU2223098C2 (ru) 2004-02-10
AT409083B (de) 2002-05-27
SK13642001A3 (sk) 2002-03-05
PL351377A1 (en) 2003-04-07
IL145559A0 (en) 2002-06-30
CA2366841A1 (en) 2000-10-12
HUP0200669A2 (hu) 2002-07-29
ES2168241T3 (es) 2005-11-01
AU1136400A (en) 2000-10-23
US6500455B1 (en) 2002-12-31

Similar Documents

Publication Publication Date Title
TR200102811T2 (tr) Oral uygulama için, tolpersiyon içeren farmasötik preparat.
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
BR0315547A (pt) Derivados de quinolina como antagonistas de crth2
DE50011582D1 (de) Neuartige dicarbonsäurederivate mit pharmazeutischen eigenschaften
NO20043367L (no) Oralt farmasoytisk preparat
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
MY128659A (en) Novel aminodicarboxylic acid derivatives having pharmaceutical properties
CY1109962T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4,5]δεκαν-2-ονης για τη θεραπεια παχυσαρκιας
EP2298416A3 (en) Sustained-release tramadol formulations with 24-hour clinical efficacy
NO20015226L (no) Tri-aryl syrederivater som PPAR reseptor ligander, farmasoytisk sammensetning omfattende samme og anvendelse av samme for fremstilling av medikament.
EA200400881A1 (ru) Азаарилпиперазины
NO20090327L (no) Nye forbindelser 384
NO20090328L (no) Nye forbindelser 385
BRPI0417043A (pt) composição farmacêutica, forma de dosagem sólida, método de manufatura de forma de dosagem sólida, e, uso da composição
ATE380023T1 (de) Orale feste pharmazeutische zusammensetzungen zur ph-abhängig mehrphasigen freisetzung
RU2695274C3 (ru) Новые композиции и способы их стабилизации
JP2007238598A5 (tr)
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
BR0314182A (pt) Formulações compreendendo um composto de indolinona
DE602006009556D1 (de) Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen
RU2004101229A (ru) Дейтерированные n-и альфа-замещенные аминоалкилэфиры дифенилакоксиуксуной кислоты, а также лекарственные средства, содержащие эти соединения
BR0311642A (pt) Formulação de divalproex de sódio de liberação aumentada
CY1112057T1 (el) Θεραπευτικος παραγων για διαταραχη επαρκειας τροφης στο στομαχι
BRPI0408270A (pt) composição farmacêutica compreendendo ácido 5-metil-2-(2'cloro-6'-fluoroanilino)fenilacético